No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Novoeight is a brand of hematological drugs used to treat hemophilia A, a genetic disorder that impairs the body's ability to form blood clots. Novoeight is a recombinant factor VIII (rFVIII) therapy, which is a type of protein replacement therapy. It is used to replace the missing clotting factor VIII in people with hemophilia A, allowing them to form blood clots and prevent bleeding episodes. Novoeight is administered via intravenous injection and is available in both a standard and a high-purity formulation.
Novoeight is manufactured by Novo Nordisk, a Danish pharmaceutical company. Other companies in the hematological drugs market include Bayer, Pfizer, Biogen, and Shire. Show Less Read more
